Company Overview of Kanyos Bio, Inc.
Kanyos Bio, Inc. develops antigen-specific immune tolerance technology for autoimmune indications, including type-1 diabetes and celiac disease. The company focuses on translating the antigen-specific immune tolerance technology to develop targeted treatments for type-1 diabetes and celiac disease. Kanyos Bio, Inc. was formerly known as Lumberjill Therapeutics, Inc. The company was incorporated in 2014 and is based in Cambridge, Massachusetts.
Founded in 2014
Key Executives for Kanyos Bio, Inc.
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3Bar Biologics Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|Tax Management Inc||United States|
|NYC2012, Inc.||United States|
|John F. Kennedy Center For The Performing Arts||United States|
Sponsored Financial Commentaries
To contact Kanyos Bio, Inc., please visit www.kanyosbio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.